Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

High-Throughput Implementation of the NanoBRET Target Engagement Intracellular Kinase Assay to Reveal Differential Compound Engagement by SIK2/3 Isoforms.

Jin HY, Tudor Y, Choi K, Shao Z, Sparling BA, McGivern JG, Symons A.

SLAS Discov. 2019 Dec 18:2472555219893277. doi: 10.1177/2472555219893277. [Epub ahead of print]

PMID:
31849250
2.

Virtual screening to identify potent sepiapterin reductase inhibitors.

Gao H, Schneider S, Andrews P, Wang K, Huang X, Sparling BA.

Bioorg Med Chem Lett. 2020 Jan 15;30(2):126793. doi: 10.1016/j.bmcl.2019.126793. Epub 2019 Nov 9.

PMID:
31740247
3.

Pharmacological Assessment of Sepiapterin Reductase Inhibition on Tactile Response in the Rat.

Meyer JT, Sparling BA, McCarty WJ, Zhang M, Soto M, Schneider S, Chen H, Roberts J, Tan H, Kornecook T, Andrews PS, Knutson CG.

J Pharmacol Exp Ther. 2019 Nov;371(2):476-486. doi: 10.1124/jpet.119.257105. Epub 2019 May 20.

PMID:
31110114
4.

Progress in the discovery of small molecule modulators of the Cys-loop superfamily receptors.

Sparling BA, DiMauro EF.

Bioorg Med Chem Lett. 2017 Aug 1;27(15):3207-3218. doi: 10.1016/j.bmcl.2017.04.073. Epub 2017 May 4. Review.

PMID:
28606760
5.

Sustainable Practices in Medicinal Chemistry Part 2: Green by Design.

Aliagas I, Berger R, Goldberg K, Nishimura RT, Reilly J, Richardson P, Richter D, Sherer EC, Sparling BA, Bryan MC.

J Med Chem. 2017 Jul 27;60(14):5955-5968. doi: 10.1021/acs.jmedchem.6b01837. Epub 2017 Apr 12. Review.

PMID:
28375009
6.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.

Graceffa RF, Boezio AA, Able J, Altmann S, Berry LM, Boezio C, Butler JR, Chu-Moyer M, Cooke M, DiMauro EF, Dineen TA, Feric Bojic E, Foti RS, Fremeau RT Jr, Guzman-Perez A, Gao H, Gunaydin H, Huang H, Huang L, Ilch C, Jarosh M, Kornecook T, Kreiman CR, La DS, Ligutti J, Milgram BC, Lin MJ, Marx IE, Nguyen HN, Peterson EA, Rescourio G, Roberts J, Schenkel L, Shimanovich R, Sparling BA, Stellwagen J, Taborn K, Vaida KR, Wang J, Yeoman J, Yu V, Zhu D, Moyer BD, Weiss MM.

J Med Chem. 2017 Jul 27;60(14):5990-6017. doi: 10.1021/acs.jmedchem.6b01850. Epub 2017 Apr 20.

PMID:
28324649
7.

Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors.

Sparling BA, Yi S, Able J, Bregman H, DiMauro EF, Foti RS, Gao H, Guzman-Perez A, Huang H, Jarosh M, Kornecook T, Ligutti J, Milgram BC, Moyer BD, Youngblood B, Yu VL, Weiss MM.

Medchemcomm. 2016 Dec 2;8(4):744-754. doi: 10.1039/c6md00578k. eCollection 2017 Apr 1.

8.

Decarboxylative Anti-Michael Addition to Olefins Mediated by Photoredox Catalysis.

Lovett GH, Sparling BA.

Org Lett. 2016 Jul 15;18(14):3494-7. doi: 10.1021/acs.orglett.6b01712. Epub 2016 Jul 1.

PMID:
27364853
9.

Total Synthesis of (-)-Nemorosone and (+)-Secohyperforin.

Sparling BA, Tucker JK, Moebius DC, Shair MD.

Org Lett. 2015 Jul 17;17(14):3398-401. doi: 10.1021/acs.orglett.5b01121. Epub 2015 Jun 30.

PMID:
26125288
10.

Enantioselective total synthesis of hyperforin.

Sparling BA, Moebius DC, Shair MD.

J Am Chem Soc. 2013 Jan 16;135(2):644-7. doi: 10.1021/ja312150d. Epub 2012 Dec 31.

PMID:
23270309
11.
12.

SmI2-promoted Reformatsky-type coupling reactions in exceptionally hindered contexts.

Sparling BA, Moslin RM, Jamison TF.

Org Lett. 2008 Mar 20;10(6):1291-4. doi: 10.1021/ol800099a. Epub 2008 Feb 27.

Supplemental Content

Loading ...
Support Center